AUS
NZ
UK
CA
USA
IND
Highlights
- MDGH gains FDA approval for moxidectin to treat river blindness.
- Ghana becomes the first river blindness-endemic country to approve moxidectin.
- MDGH’s cost-plus pricing ensures affordable treatment for underserved populations.
Medicines Development for Global Health (MDGH) is transforming the treatment landscape for neglected diseases, particularly in underserved regions. Operating as a not-for-profit, MDGH prioritizes diseases that lack a commercial market. Its approach aims to bridge gaps in access to essential medicines, a pressing issue highlighted by the World Health Organization, which reports that billions lack even basic medications.
MDGH’s current initiatives include the development of two medicines, moxidectin and dovramilast, targeting up to eight neglected diseases. Moxidectin, licensed from the World Health Organization, has emerged as a pivotal treatment for river blindness. This parasitic disease, primarily affecting populations in Africa, causes severe itching, disfigurement, and permanent blindness. Despite existing efforts using ivermectin, eliminating the disease remains challenging due to limitations in current programs.
FDA Approval and Recognition
Moxidectin secured approval from the United States Food and Drug Administration (FDA), marking a significant milestone as the first FDA-approved treatment for river blindness in two decades. This achievement also earned MDGH an FDA Priority Review Voucher, incentivizing further investment in neglected diseases.
Breakthrough in Ghana
The Ghana Food and Drugs Authority recently granted regulatory approval for moxidectin, making Ghana the first endemic country to approve the medicine. This decision paves the way for a pilot treatment program in Twifo Atti-Morkwa district, set to commence in January 2025. The district was prioritized due to higher-than-expected disease prevalence despite previous ivermectin treatments.
Moxidectin has demonstrated superior efficacy compared to ivermectin, reducing skin parasite levels more effectively and for longer durations, potentially accelerating progress toward eliminating parasite transmission.
A New Model for Medicine Delivery
MDGH’s approach sets a precedent in neglected disease treatment. By operating independently of multinational or generic pharmaceutical companies, it has achieved regulatory approval and ensures cost-plus pricing for low- and middle-income countries.
This innovative strategy reflects a commitment to equitable healthcare access, with MDGH collaborating with stakeholders to optimize moxidectin’s deployment for elimination goals. As the pilot program in Ghana unfolds, it represents a critical step in reducing the burden of river blindness and advancing health equity.
